Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Association Between Axillary Surgical Management and Survival in Patients with de novo Metastatic Breast Cancer.

Annals of surgical oncology·2026
Same author

Association Between Axillary Surgical Management and Survival for Patients With De Novo Metastatic Breast Cancer.

Annals of surgical oncology·2026
Same author

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

Nature communications·2026
Same author

The preponderance of genetic variations in paediatric pulmonary hypertension.

Respiratory medicine and research·2026
Same author

Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays.

Analytical chemistry·2026
Same author

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Sep 26, 2025

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.4K

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach.

Ezgi Tulukcuoglu Guneri1,2, Emile Lakis1,2, Ismail Hajji1,2

  • 1Laboratoire Physico Chimie Curie, CNRS UMR168, Institut Curie, 75005 Paris, France.

Cancers
|April 23, 2022
PubMed
Summary
This summary is machine-generated.

This study introduces a microfluidic chip to quantify HER2-HER3 dimerization in single circulating tumor cells (CTCs). This technology aids in understanding HER2-positive breast cancer and personalizing patient treatment strategies.

Keywords:
HER2HER3 dimerizationcirculating tumor cellsmicrofluidicproximity ligation assay

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.7K

Related Experiment Videos

Last Updated: Sep 26, 2025

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.4K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.7K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Molecular Diagnostics

Background:

  • Microfluidics enables advanced detection of circulating tumor biomarkers for improved disease understanding and patient management.
  • Circulating tumor cells (CTCs) are critical biomarkers, especially in breast cancer.
  • HER2-positive breast cancer involves HER2 protein amplification, and HER2-HER3 dimerization blockade enhances therapeutic outcomes.

Purpose of the Study:

  • To develop a microfluidic approach for quantifying HER2-HER3 dimerization at the single CTC level.
  • To integrate CTC capture, identification, and Proximity Ligation Assay (PLA) on a single chip.
  • To assess the clinical utility of this method for HER2-positive breast cancer patients.

Main Methods:

  • Development of a microfluidic chip for simultaneous CTC capture and identification.
  • On-chip implementation of Proximity Ligation Assay (PLA) to quantify HER2-HER3 dimerization.
  • Optimization using cancer cell lines with varying HER2 expression levels.
  • Validation with clinical patient samples.

Main Results:

  • Successful on-chip quantification of HER2-HER3 dimerization in single CTCs.
  • Demonstrated potential using cell lines with diverse HER2 overexpression.
  • Validated clinical applicability with patient samples, including those undergoing HER2-targeted therapy.

Conclusions:

  • The developed microfluidic PLA chip offers a novel method for single CTC characterization.
  • This technology can precisely quantify HER2-HER3 dimerization, crucial for HER2-positive breast cancer.
  • The approach holds significant promise for improving patient management and guiding targeted therapies.